HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells
Clara Alcon(United Biscuits (United Kingdom)), Joan Montero(United Biscuits (United Kingdom))
Cited by 18
Related Papers
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
|Cancer Cell|2016|304
Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
|Cancer Discovery|2016|209
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity
|Nature Cancer|2020|110